Just announced: The American Academy of Pediatrics (AAP) guidance recommends exome and genome as first-line tests for global developmental delay (GDD) and intellectual disability (ID). Read more here►

MSH2 Exons 1-7 Inversion Analysis

ATTENTION: This test is being retired. The last day to order this test is September 16, 2025. Samples must be received by September 30, 2025, or your order will be canceled.

New York
Approved


Genes

MSH2

Conditions

  • Colorectal Cancer
  • Endometrial Cancer
  • Lynch Syndrome
  • Ovarian Cancer
  • Pancreatic Cancer

Clinical Utility

  • Identify the genetic basis of cancer for individuals who have features and/or a family history consistent with one of the hereditary cancer syndromes described above
  • Determine appropriate clinical management recommendations based on a molecular diagnosis
  • Identify family members at-risk to develop features associated with a specific hereditary cancer syndrome

Lab Method

  • PCR & Electrophoresis

Test Code

J006

CPT Codes*

81479x3

ABN Required

No

Turnaround Time**

3 weeks

Preferred Specimen

2-5 mL Blood - Lavender Top Tube

Alternative Specimen

Buccal Swabs

*The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

**Turnaround times are estimates and begin once the sample(s) begin processing at the GeneDx lab and could be extended in situations outside GeneDx’s control.